Warren Slams RFK Jr.’s Secrecy on Trump’s Big Pharma Deals; Releases New HHS Response Raising Questions About Administration’s Savings Estimate

In a new response to Warren, RFK Jr. claims TrumpRx does not store prescription information — raising questions about whether Administration savings claims were “made up out of thin air.” “Your ongoing refusal to release these deals raises questions about whether the Trump administration is trying to hide the fact that it is giving billion-dollar handouts to Big Pharma without getting anything meaningful in return for Americans.” Text of Letter (PDF) | RFK Jr. Response (PDF) Washington, D.C. — U.S. Senator Elizabeth Warren (D-Mass.) slammed Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. for his refusal to release the Trump administration’s secret pricing deals with drug companies and for breaking a promise he made to Warren in a recent hearing . Senator Warren also released a new response from Secretary Kennedy that raises doubts about the accuracy of the Trump administration’s claims of cost savings from the secret pharma deals. The letter comes after Dr. Mehmet Oz, the CMS Administrator, admitted that President Trump’s “Most-Favored-Nation” (MFN) prescription drug pricing deals will expire at the end of the President’s term. The drug manufacturers that entered into these deals will benefit from huge tariff exemptions for branded drugs and vouchers to fast-track approvals for new products – lucrative perks that they received while doing little to reduce drug costs for the American public. At a recent Senate Finance Committee hearing , Kennedy committed to Warren that he would disclose the administration’s pricing deals with drug companies, stating, “I’m happy to make the deals available.” Senator Warren pressed Kennedy to make good on his promise in a follow-up letter , but Kennedy has failed to do so. Now, in a new response to Warren, Kennedy once again dodged his promise to release details of the secret drug pricing deals to the American public and instead revealed new information that casts serious doubts on the Trump administration’s claims of savings for Americans. The same week that Kennedy replied to Warren, the White House claimed that TrumpRx had saved Americans more than $700 million. But in his response, Kennedy admitted that TrumpRx “does not store any patient, health, or prescription information.” Without this information, the accuracy of any claims of savings made by the Trump administration is unreliable. “On its face, this is an admission of failure,” said the senator . “But your response to me raises questions about whether even that estimate was made up out of thin air.” The senator also raised concerns about the administration’s efforts to raise drug prices overseas in what would be a boon for drug companies. Reports indicate that the Trump administration is “launching a full-scale charm offensive across Europe to persuade governments…to pay more for medicines” — and using the threat of tariffs to strong-arm countries if that does not work. Drug companies are reportedly “already leveraging the pressure from the U.S. to try to get European countries to pay more” for prescription drugs. At the same time, drug manufacturers, including the ones participating in these MFN deals, continue to raise drug prices undeterred. In January, prices increased for 872 drugs, and for hundreds more throughout the spring and summer. “You committed to bringing ‘radical transparency’ to the Department of Health and Human Services (HHS), but your ongoing refusal to release these deals raises questions about whether the Trump administration is trying to hide the fact that it is giving billion-dollar handouts to Big Pharma without getting anything meaningful in return for Americans,” wrote Senator Warren . “Americans deserve to know whether the deals the administration is cutting with Big Pharma will lower their prescription drug costs — or just further enrich big drug companies,” continued Senator Warren. Senator Warren asked Kennedy to provide answers to her questions regarding these prescription drug pricing deals no later than August 27, 2026. Senator Warren has led efforts to push back against Big Pharma and use every tool available in government to lower drug prices: In May 2026, Senators Elizabeth Warren (D-Mass.) and Josh Hawley (R-Mo.), alongside Representatives Diana Harshbarger (R-Tenn.) and Jake Auchincloss (D-Mass.), reintroduced the Patients Before Monopolies (PBM) Act with expanded bipartisan support, indicating growing momentum for a policy that will prohibit joint ownership of pharmacy benefit managers (PBMs) and pharmacies, a gross conflict of interest that enables these companies to enrich themselves at the expense of patients and independent pharmacies. In April 2026, Senator Elizabeth Warren pressed Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. on multiple commitments she secured during an exchange in a Senate Finance Committee hearing. In April 2026, at a hearing of the Senate Finance Committee, Senator Elizabeth Warren pressed Secretary of the Department of Health and Human Services (HHS) Robert F. Kennedy Jr. on TrumpRx, revealing how President Trump’s marquee drug pricing effort often provides higher prices for Americans while boosting Big Pharma’s bottom line. In April 2026, Senator Elizabeth Warren, a member of the Senate Finance Committee; Ron Wyden (D-Ore.), Ranking Member of the Senate Finance Committee; and 18 Senate Democrats introduced new legislation to force the Trump Administration to disclose the terms of deals signed with more than a dozen of the largest pharmaceutical companies and conduct an independent analysis to determine whether American families will see lower prices from the deals. In February 2026, Senators Elizabeth Warren and Josh Hawley (R-Mo.) introduced the Break Up Big Medicine Act to address rampant consolidation in the health care industry that drives up prices, squashes competition, and fuels corporate greed. In November 2025, Senator Elizabeth Warren, Senate Minority Leader Chuck Schumer (D-N.Y.), and Finance Committee Ranking Member Ron Wyden (D-Ore.) led 25 Senate Democrats in slamming the Trump administration for its failure to address rising health care costs for American families. In June 2025, Senator Elizabeth Warren, a member of the Senate Finance Committee, and Representative Jan Schakowsky (D-Ill.) wrote to Abbvie, Pfizer, Amgen, Merck, and Johnson & Johnson, calling them out for taking advantage of tax loopholes created by President Trump’s 2017 tax bill and lobbying for even more tax giveaways. In March 2025, Senator Elizabeth Warren, along with Senate Finance Ranking Member Ron Wyden (D-Ore.) and Senate Health, Education, Labor, and Pensions (HELP) Ranking Member Bernie Sanders (I-Vt.), pressed Department of Health and Human Services Secretary Robert F. Kennedy Jr. on his promises to “clean up corruption” and “stop the revolving door between industry and government,” following reports that Kennedy attended multiple “million-dollar” dinners with Big Pharma executives at President Trump’s Mar-a-Lago club. ###